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Anne Hoorens5, An Vermeulen6, Wim Ceelen6,7 & Chris Vervaet1*
patients with advanced ovarian cancer develop recurrence despite initial treatment response to 
standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a 
limited peritoneal exposure time of chemotherapeutics. paclitaxel-loaded genipin-crosslinked gelatin 
microspheres (PTX-GP-MS) are evaluated for the treatment of microscopic peritoneal carcinomatosis 
and prevention of recurrent disease. The highest drug load (39.2 µg PTX/mg MS) was obtained by 
immersion of GP-MS in aqueous PTX nanosuspension (PTXnano-GP-MS) instead of ethanolic PTX 
solution (PTXetoH-GP-MS). PTX release from PTX-GP-MS was prolonged. PTXnano-GP-MS displayed 
a more controlled release compared to a biphasic release from PTXetoH-GP-MS. Anticancer efficacy 
of IP PTX-GP-MS (PTXetoH-GP-MS, D = 7.5 mg PTX/kg; PTXnano-GP-MS D = 7.5 and 35 mg PTX/kg), 
IP nanoparticular albumin-bound PTX (D = 35 mg PTX/kg) and controls (0.9% NaCl, blank GP-MS) 
was evaluated in a microscopic peritoneal carcinomatosis xenograft mouse model. PTXnano-GP-MS 
showed superior anticancer efficacy with significant increased survival time, decreased peritoneal 
carcinomatosis index score and ascites incidence. However, prolonged PTX release over 14 days from 
PTXnano-GP-MS caused drug-related toxicity in 27% of high-dosed PTXnano-GP-MS-treated mice. Dose 
simulations for PTXnano-GP-MS demonstrated an optimal survival without drug-induced toxicity in a 
range of 7.5–15 mg PTX/kg. Low-dosed PTXnano-GP-MS can be a promising IP drug delivery system to 
prevent recurrent ovarian cancer.
The majority of ovarian cancer (OC) patients (>70%) is diagnosed at an advanced stage of the disease 
(International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) with peritoneal metastases pres-
ent since there are no specific symptoms and effective screening methods are lacking. The main symptoms are 
abdominal pain and swelling, gastrointestinal complaints and occasionally urinary symptoms or vaginal bleed-
ing1–6. The stage of OC strongly determines survival; prognosis at FIGO stages III and IV is poor with a 5-year 
overall survival rate of 27 and 21%, respectively1,7.
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Standard combination therapy of cytoreductive surgery (CRS) followed by six cycles of intravenous (IV) 
platinum- and taxane-based chemotherapy initially achieves complete remission in 80% of advanced OC patients. 
Unfortunately, most of the patients will relapse within 5 years because minimal residual disease persists in the 
peritoneal cavity despite a (nearly) complete cytoreduction. Adjuvant intraperitoneal (IP) chemotherapy has been 
added to the treatment modality of selected patients to improve treatment outcome since metastatic disease is 
mainly limited to the abdominal cavity. IP chemotherapy can be administered postoperatively via a catheter or as 
a (hyperthermic) intraoperative chemoperfusion ((H)IPEC) as a part of the surgical procedure1,3,8,9. The rationale 
of IP drug delivery is based on the existence of a peritoneal-plasma barrier. Peritoneal tumors can be exposed 
to a higher concentration of the cytotoxic agent with moderate systemic drug exposure, thereby reducing toxic 
side effects since the peritoneal clearance is much slower than the systemic clearance8–11. Paclitaxel (PTX) is the-
oretically an ideal chemotherapeutic agent for IP application as it has a peritoneal/plasma concentration ratio of 
>1000 and displays a significant first pass effect9,12–14.
Several large, prospective randomized phase III clinical trials showed that adjuvant IP chemotherapy signif-
icantly improved overall survival of patients with advanced ovarian cancer2,15–17. However, the risk of recurrent 
peritoneal disease remains high18,19. This can be partly attributed to a short residence time of the chemothera-
peutics in the abdominal cavity and the single administration of HIPEC18,20. Up to now, there are no products 
approved by the US Food and Drug Administration (FDA) specifically for IP application. Consequently, current 
IP therapy is based on off-label use of IV chemotherapeutics. These conventional low molecular weight drugs 
are rapidly absorbed from the peritoneal cavity and lack tumor specificity8,20,21. Additionally, IP chemotherapy is 
only recommended for patients with optimally debulked peritoneal disease or microscopic disease because of the 
limited penetration depth of drugs directly into the tumor by free-surface diffusion8,10,21. A prolonged residence 
time of chemotherapeutics would avoid rapid clearance of the drug from the peritoneal cavity, thereby maintain-
ing a local drug concentration gradient as the driving force for drug diffusion into the tumor, improving tumor 
penetration since drug diffusion is a slow process10,20.
Drug delivery systems designed for IP application have been investigated to overcome the challenges of IP 
therapy and further improve treatment of advanced ovarian cancer. Drug delivery strategies include micro-
spheres, nanoparticles, liposomes, micelles, implants and injectable depots10,13. Nanoparticulate systems (nan-
oparticles, liposomes, micelles) seem interesting delivery systems for IP administration since they can be easily 
modified for targeted drug delivery and can incorporate hydrophobic chemotherapeutic agents. Two nanopar-
ticulate formulations have been applied in phase I clinical trials for IP use, NanoTax®, a 600–700 nm rod shaped 
reservoir of PTX, and Abraxane®, nanoparticular albumin-bound PTX (nab-PTX) with a size of 130 nm. Both 
studies showed higher levels of PTX in the peritoneal cavity compared with IV administrated PTX18. But, due to 
their small size, they are rapidly absorbed from the abdominal cavity and their residence time is often insufficient 
to permit efficient tumor penetration8,18,20. Therefore, dispersion of a nanoparticulate system into a depot system 
might be an interesting approach to overcome these limitations. Microparticles, on the other hand, are retained 
in the peritoneal cavity because of their size (>1 µm). Drugs can be gradually released over time, thereby improv-
ing local bioavailability and reducing systemic toxicity. It should be noted that larger particles tend to induce 
inflammatory responses and peritoneal adhesions8,20,22. Paclimer®, biodegradable PTX microspheres based on 
a polyphosphoester polymer, was evaluated in a phase I clinical trial in recurrent ovarian cancer. A continu-
ous IP PTX release over 8 weeks was demonstrated but the product was discontinued because of inflammatory 
responses due to the presence of residual polymer filaments23. Hydrogels can also form an IP sustained release 
depot. As homogenous distribution of the formulation throughout the peritoneal cavity is difficult to achieve 
using hydrogels due to viscosity issues, thermosensitive hydrogels were developed which are liquid at room tem-
perature and form a non-flowing gel in situ20,24,25. Many biodegradable hydrogels loaded with a chemotherapeutic 
agent have been successfully developed and evaluation in peritoneal carcinomatosis models in animals showed 
superior antitumoral activity compared to the unentrapped cytostatic drug26–29. However, an injectable hydrogel 
formulation of PTX, Oncogel®, failed to show an impact on overall tumor response in a phase II b clinical trial 
following intratumoral administration despite good tolerance, favorable pharmacokinetics and preliminary anti-
cancer activity30,31. Currently, there are no ongoing clinical trials investigating the potential of depot systems in 
the treatment of ovarian cancer.
Previously, genipin-crosslinked gelatin microspheres (GP-MS) were developed for IP application and were 
shown effective for the prevention of peritoneal adhesions, a common complication after CRS32. In the pres-
ent study paclitaxel (PTX) is encapsulated in GP-MS, and its drug release behavior is studied. The effect of 
PTX-loaded GP-MS on the viability of ovarian cancer cell lines is also investigated. The efficacy of a prolonged 
IP PTX release from different types of PTX-loaded GP-MS (PTX-GP-MS) to eradicate microscopic peritoneal 
disease of ovarian origin and further prevent recurrence of peritoneal disease is evaluated in a human xenograft 
mouse model.
Materials and Methods
incorporation of paclitaxel into genipin-crosslinked gelatin microspheres. Genipin-crosslinked 
gelatin microspheres with an average size of 50 µm were prepared as described in De Clercq et al., 2016.
GP-MS were loaded with PTX by immersion in an ethanolic PTX solution. 200 mg GP-MS with different 
degrees of crosslinking (7, 25, 40, 60 and 70%) were immersed in 2 ml of a 1, 2.5 or 5 mg/ml PTX (purity of 
>99%, LC laboratories, Woburn, MA, USA) ethanol/distilled water (75/25, v/v) (absolute ethanol, VWR chem-
icals, Fontenay-sous-Bois cedex, France) solution under slow magnetic stirring. After 3 hours, GP-MS were vac-
uum filtered and washed with absolute ethanol (VWR chemicals) to remove unentrapped PTX from the surface. 
PTX-loaded GP-MS were lyophilised for 24 hours at −50 °C and 1 mbar.
GP-MS were also loaded by immersion in an aqueous PTX-nanosuspension. Initially, PTX-nanocrystals 
were prepared using a wet milling technique13. Pluronic® F-127/PTX (Pluronic® F-127, Sigma-Aldrich, Bornem, 
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Belgium) (PTX purity of >99%, LC laboratories) in a 1/4 ratio was transferred in a 20 ml vial containing 5 ml 0.9% 
sodium chloride solution (Sigma-Aldrich) and 30 g zirconium oxide beads (Netzsch zetabeads, Ghislenghien, 
Belgium) with a diameter of 0.5 mm as milling pearls. The vials were placed on a roller-mill and grinded at 
150 rpm for 60 hours. The nanocrystals were lyophilised for 24 hours at −50 °C and 1 mbar. Particle size and 
polydispersity index (PI) of the PTX nanocrystals were determined by dynamic light scattering, using a Zetasizer 
3000 (Malvern Instruments, Worcestershire, UK). GP-MS (50, 100 or 200 mg) were immersed for 3 hours in 2 ml 
aqueous PTX nanosuspension, diluted using 0.9% sodium chloride solution to a concentration of 1, 2.5 or 5 mg 
PTX/ml. PTX-loaded GP-MS were collected by vacuum filtration and washed using distilled water to remove 
unentrapped PTX from the surface. PTXnano-GP-MS were lyophilised for 24 hours at −50 °C and 1 mbar.
Loading efficiency of PTX in GP-MS was analysed by an in-house UPLC-MS/MS after degradation of the 
microspheres. To a test tube containing 10 mg blank GP-MS, 960 µl 2 N hydrogen chloride (purity of 37%, 
Sigma-Aldrich) was added and 40 µl of a PTX standard was spiked. PTX-GP-MS were weighed (10 mg) in a test 
tube and 1 ml 2 N hydrogen chloride (purity of 37%, Sigma-Aldrich) was added33. After incubating the samples 
for 2 hours at 60 °C, 4 ml ethanol (VWR chemicals) was added. Subsequently, the samples were vortexed and 
centrifuged at 3000 rpm for 5 minutes. The collected supernatant (500 µl) was transferred to a glass vial (Filter 
Service, Eupen, Belgium) with insert (Agilent Technologies, Diegem, Belgium), to which 500 µl deionized water 
(Synergy 185-millipore, Prod 18.2 MΩ.cm, Bedford, USA) and 50 µl IS, were added. After vortexing, the vials 
were placed in the autosampler thermostated at 5 °C. Aliquots of 1 µl were injected for analysis. After integration 
of the peaks, the calculated concentration of incorporated PTX, expressed as µg/ml, was converted to the amount 
of incorporated PTX (µg) per mass (mg) MS and the incorporation efficiency (IE) of PTX in MS was calculated 
using Eq. 1.
= ×IE (%) amount of PTX per mg MS
maximum amount of PTX per mg MS
100
(1)
In vitro PTX release from paclitaxel-loaded GP-MS. In vitro release of PTX from PTX-loaded GP-MS 
was evaluated by a membrane-less method. 20 mg lyophilised PTX-loaded GP-MS was immersed in 10 ml release 
medium, phosphate buffered saline buffer (PBS) with a pH of 7.4 supplemented with 0.1% w/v polysorbate 80 
(Tween 80, Fagron, Nazareth, Belgium) in closed test tubes. Drug release experiments were performed at 37 °C for 
21 days under gentle shaking conditions. At specific time points, test tubes were centrifuged, and 1 ml of release 
medium was sampled. The withdrawn medium was replaced by 1 ml of fresh buffer solution. Before sampling, test 
tubes were centrifuged to avoid pipetting of GP-MS. Each experiment was performed in triplicate.
Concentrations of PTX and its stereoisomer 7-epi PTX in the release medium were determined by UPLC-MS/
MS. After integration of the peaks, total cumulative concentration of released PTX (sum of PTX and 7-epi PTX), 
expressed as ng/ml, was calculated. Percentage PTX release (%) was calculated using Eq. 2.
= ×PTX release (%) total cumulative concentration of released PTX (ng/ml)
maximum released PTX concentration (ng/ml)
100
(2)
Influence of PTX-loaded GP-MS on ovarian cancer cell viability. Human ovarian cancer (OC) cell 
lines SK-OV-3 and OVCAR-3 were purchased from American Type Culture Collection. SK-OV-3 Luc IP1 is iso-
lated after in vivo selection of intraperitoneal (IP) injected SK-OV-3 Luc cells34. OVCAR-3 was cultured in RPMI 
1640 medium (Life Technologies, ThermoFisher, Ghent, Belgium) supplemented with 10% fetal bovine serum 
(FBS, Sigma-Aldrich) and 2% penicillin/streptomycin (Life technologies). SK-OV-3 (Luc IP1) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies), supplemented with 10% FBS (Sigma-Aldrich) 
and 2% penicillin/streptomycin (Life Technologies).
CellTiter Glo 2.0 Luminescent Assay was performed to determine cell viability based on quantifica-
tion of adenosine triphosphate (ATP). OC cells were seeded as monolayers in opaque white 96-well plates 
(ThermoFisher). Seeding density depended on incubation time and is displayed in Table 1. Subsequently, after 
24 hours cells were exposed to multiple concentrations of different types (7, 25, 40 and 60% degree of crosslink-
ing) of PTX-ethanolic loaded GP-MS (PTXEtOH-GP-MS). Cells were also exposed to a concentration range of 
GP-MS loaded with PTX-nanosuspension (PTXnano-GP-MS) and to a PTX solution. PTX-loaded GP-MS were 
dispersed in an appropriate medium and diluted until a concentration of 1 to 1000 nM of PTX was achieved. 10 µl 
of test formulation was added to the cells. Untreated cells were used as a control. After 24, 72, 168 or 336 hours 
of incubation, 100 µl CellTiter Glo 2.0 Reagens (Promega, Leiden, The Netherlands) was added to each well. 
Luminescence was measured after 10 minutes using a Paradigm Detection Platform and analysed with Soft Max 
Incubation time (day) Cells/well
1 30 000
2 25 000
4 20 000
7 10 000
14 5 000
Table 1. Seeding density of cells.
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Pro 6.1 Software (BIO-RAD laboratories, Hemel Hempstead, United Kingdom). All experiments were performed 
in triplicate. The cytotoxic inhibitory concentration 50% (IC50)-values were calculated using nonlinear regression 
analysis (dose-response inhibition) in Graphpad Prism™ 6 (Graphpad software, La Jolla, CA, USA). Statistical 
analysis was performed using post-hoc Bonferroni test, a p-value < 0.05 was considered statistically significant.
Efficacy of PTX-microspheres in a microscopic peritoneal carcinomatosis xenograft model. All 
animal experiments were approved by the Animal Ethics Committee of the Faculty of Medicine at Ghent 
University (ECD 17/83) and were performed according to Belgian and European legislature on animal welfare. 
Mice were kept in standard housing conditions with water and food ad libitum and a 12 h light/dark cycle. Mice 
were evaluated daily for pain or discomfort, and “The Guidelines for the welfare and use of animals in cancer 
research” were strictly followed for distention of the abdomen, general condition and other clinical signs as pre-
scribed by The National Cancer Research Institute. All procedures were performed under general anesthesia 
(Sevorane®, Abbott, Belgium or Isoflo®, Ecuphar, Oostkamp, Belgium), and analgesia (ketoprofen, 5 mg/kg) was 
administered if necessary.
Six-week old female Balb/c Nu mice (BALB/cOlaHsd-Foxn1nu, Envigo, Horst, The Netherlands) were con-
ditioned one week before the start of the study. A microscopic peritoneal carcinomatosis model was used to 
evaluate the effect of IP treatment on microscopic disease similar to the post-cytoreductive surgery state and the 
potential to prevent recurrent disease35–37. Mice were injected IP with 2 × 106 SK-OV-3-Luc IP1 cells suspended 
in 1 ml 0.9% saline. Mice (10–12/group) were injected IP with PTX treatment; 50 mg of PTX-GP-MS suspended 
in 2 ml of 0.9% saline or nab-PTX (Abraxane®, Celgene Europe, Uxbridge, UK) 1 day after engraftment with 
tumor cells, referred to as day 0 of the study. Control animals (11/group) were IP injected with 2 ml of 0.9% saline 
or 50 mg of blank GP-MS suspended in 2 ml of 0.9% saline. The treatment schedule is displayed in Table 2. GP-MS 
with a 40% crosslinking degree were selected since a peritoneal residence time of 14 days is ensured32.
Animals were continuously evaluated from the day of treatment until occurrence of death, attainment of 
predefined endpoints or until the end of the study (90 days post-treatment). General conditions (activity, feces 
evaluation, behavior pattern and other clinical signs), body weight and mortality were carefully monitored. Mice 
were euthanized when they met following humane endpoints: excessive weight loss (body weight loss of ≥20% 
at any timepoint or ≥15% maintained for 72 h compared with pre-treatment weight), presence of ascites and 
abnormal behavior.
Weekly, bioluminescence imaging (BLI) was performed for tumor growth follow-up of each mouse. Mice were 
injected IP with 0.2 ml of D-luciferin (15 mg/ml; PerkinElmer, Zaventem, Belgium) 10 minutes prior to BLI. After 
10 min, bioluminescence images were acquired by the IVIS Lumina II system (PerkinElmer). Luminescence was 
quantified using the Living Image® 4.3.1 software (PerkinElmer).
In case of death, after euthanasia when humane endpoints were reached or at the final day of the study, a 
midline laparotomy was performed, and the abdominal cavity was exposed and photographed. Each mouse was 
assigned a Peritoneal Carcinomatosis Index (PCI) score. The abdominal cavity was divided in 13 standard regions 
as described by Sugarbaker38 and adapted for rodents by Klaver39. For each region a score from 0 to 3 was given 
based on size and quantity of tumor nodules (Fig. 1). Furthermore, an ascites score was given of 0 (no ascites pres-
ent) or 1 (ascites present) to all animals. Survival time of each mouse was assessed. The therapeutic efficacy was 
Treatment PTX dose (mg/kg) Number of mice
0.9% saline 0 11
Blank GP-MS 0 11
PTXEtOH GP-MS 7.5 10
PTXnano GP-MS 7.5 11
PTXnano GP-MS 35 11
Nab-PTX 35 12
Table 2. Different intraperitoneal treatment groups and their paclitaxel dose in mg per kg body weight.
Figure 1. Peritoneal carcinomatosis index (PCI) in mice. Visual exploration of the 13 standard regions of the 
abdominal cavity for PCI scoring was carried out using magnifiers (copy from Derrien A. et al.87).
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measured as an increase in overall survival time compared to no treatment (i.e. 0.9% saline). Increase in life span 
(ILS) was calculated as median survival time treatment minus median survival time control, % ILS was calculated 
as (median survival time treatment/median survival time control *100) minus 100.
Samples were taken from cecum, jejunum, peritoneum/abdominal wall, liver, pancreas, spleen, and if appli-
cable, tumor for histopathological examination. All samples were fixed immediately by immersion in 4% para-
formaldehyde in PBS for 72 h and embedded in paraffin. The tissues were then serially sectioned and stained with 
hematoxylin and eosin (H&E). Slides were analyzed in a blinded manner and microscopic images were taken with 
a light microscope (ColorView I, BX43F, Olympus, Tokyo, Japan).
Immunohistochemical staining was performed with Paired Boxed Gene 8 (PAX-8) polyclonal antibody 
(Proteintech), dilution 1/400, using an automatic immunostainer (Benchmark XT; Ventana Medical Systems, 
Oro Valley, AZ, USA), according to the manufacturer’s instructions. Visualization for all antibodies was achieved 
with the ultraView Universal DAB Detection kit (Ventana Medical Systems).
Statistical analysis was performed using Graphpad PrismTM 5.2 (Graphpad Software, Inc.; La Jolla, CA, USA). 
In vivo data were analysed using non-parametric tests (Mann-Whitney-U, Kruskall-Wallis and Dunn’s method). 
Survival analysis was estimated using the Kaplan-Meier method and survival differences between groups were 
evaluated using the log-rank test. A p-value < 0.05 was considered to indicate statistical significance.
Pharmacokinetics of PTX-treatments. Blood microsamples were taken daily from the tail vein until 
14 days post-treatment. 10 µl blood was spotted on a blood spot card (PerkinElmer 226 Bioanalysis RUO Card, 
Perkin Elmer, Greenville, USA). PTX concentration of dried blood spot (DBS) samples was determined by a previ-
ously developed UPLC-MS/MS methode40. The lower limit of quantification of PTX in a DBS sample was 1 ng/ml. 
The method imprecision was less than 14.6% and bias was less than ±11.9%.
Numerical deconvolution was performed using Phoenix WinNonlin® IVIVC Toolkit 7.0 (Certara LP, St. 
Louis, Missouri, USA) to evaluate the percent of drug absorbed in vivo from the PTX-formulations.
The individual predicted blood and peritoneal PTX profiles were obtained from a population pharmacoki-
netic (PK) model, carried out in NONMEM® (version 7.3, Icon Development Solutions, Ellicott City, MD, USA). 
PK parameters, peak concentration (Cmax), time-to-peak concentration (tmax) and area under the curve (AUC), 
were predicted from the PK model.
A pharmacokinetic-pharmacodynamic (PKPD) model was developed in NONMEM® using the predicted 
peritoneal concentrations as the time-varying input for the effect of PTX-treatments on survival outcome and 
blood concentrations were considered to be responsible for toxicity-induced death. Details of the PKPD model 
are described in Fie X. et al.41.
Evaluation of ccCK18 as a biomarker in ovarian cancer. During the survival study, blood of the differ-
ent PTX treatment and control groups was analyzed to determine the concentration of caspase-cleaved cytokera-
tin 18 (ccCK18) in order to evaluate its potential as a PD biomarker to monitor treatment response in microscopic 
peritoneal disease of ovarian origin. Blood samples were taken twice a week from the tail vein during the survival 
study and animals were pooled in time. Blood was centrifuged for plasma collection. Apoptosis-associated ccK18 
concentrations were quantitatively determined in plasma using a solid-phase sandwich enzyme immunoassay, 
M30 Apoptosense® enzyme-linked immunosorbent assay (PEVIVA®; VLVbio, Sundbyberg, Sweden) in accord-
ance with the manufacturer’s instructions. The detection limit of the assay was 25 U/l.
ethics approval. All animal experiments were approved by the Animal Ethics Committee of the Faculty of 
Medicine at Ghent University (ECD 17/83).
Results
incorporation of paclitaxel into genipin-crosslinked gelatin microspheres. In earlier work, 
GP-MS were developed for IP administration, and their applicability to prevent post-operative peritoneal adhe-
sions was demonstrated32. Based on the slow degradation rate of GP-MS (as a function of the crosslinking degree) 
these systems could also be applied to provide sustained intraperitoneal delivery of a chemotherapeutic agent. 
Therefore, the GP-MS were loaded with PTX. After crosslinking the GP-MS, they were loaded with PTX via 
immersion in a PTX-containing medium. Since a hydrophilic environment is preferred for this drug loading 
step to allow GP-MS swelling and to maximize PTX penetration into GP-MS, PTX was dissolved in a 75/25 v/v 
ethanol/water mixture to allow partial swelling of the microspheres and to provide sufficient solubility of PTX in 
the loading medium. The highest absolute amount of PTX was incorporated into GP-MS using a loading solu-
tion with the highest PTX concentration. However, incorporation efficiency reduced as a function of the PTX 
concentration in the loading solution (Table 3). At higher crosslinking degree less PTX was incorporated in the 
microspheres (Table 4) as drug diffusion into GP-MS is probably physically hindered due to the intramolecular 
network of genipin32. Overall, the PTX load of the GP-MS remained low. Incorporation of PTX was improved 
when GP-MS were loaded by immersion in an aqueous PTX nanosuspension (Table 3). The PTX nanocrystals 
had a particle size of 283.7 ± 1.2 nm and a polydispersity index of 0.16. The PTX load in these GP-MS was three-
fold higher compared to the procedure with an ethanolic PTX solution. Since the PTX nanocrystals were diluted 
in physiological saline, GP-MS could maximally swell during incorporation and hence diffusion of PTX into the 
microspheres is enhanced.
By adjusting the settings during the loading procedure (microsphere mass, volume and type of loading 
medium, concentration PTX in nanosuspension), the amount of PTX encapsulated in the microspheres could 
be easily varied, with a maximum PTX load of 39.2 ± 6.5 µg PTX/mg MS (Table 5). Varying the MS crosslinking 
degree yielded similar PTX loads for the PTX nanosuspension (data not shown), while the effect of this parameter 
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was more pronounced when GP-MS were loaded with a PTX-ethanolic solution, indicating that the type of load-
ing medium determines the efficiency of PTX incorporation in GP-MS.
In vitro PTX release from paclitaxel-loaded GP-MS. Cumulative release of PTX from PTX-GP-MS is 
calculated as the sum of PTX and 7-epi PTX. PTX has a complex structure with several hydrolytically sensitive 
ester groups and a chiral center that readily undergoes epimerization. Due to its instability in an aqueous environ-
ment, the stereoisomer 7-epi-PTX was abdundantly detected in drug release samples. No other PTX degradation 
products were present. Stereoisomer 7-epi PTX is thermodynamically stable and its mechanism of action is iden-
tical to PTX42–45. Drug release profiles are displayed in Fig. 2.
GP-MS loaded with an ethanolic PTX solution and PTX nanosuspension showed both a sustained PTX 
release over three weeks. Drug release from PTXEtOH-GP-MS shows a biphasic profile with an initial burst release 
during the first day followed by a sustained release. After 3 days 62.0 ± 4.0% PTX is released from 7% crosslinked 
PTXEtOH-GP-MS, and visual inspection showed that these microspheres were degraded. No significant differences 
in release profile were observed between PTXEtOH microspheres with a 40 and 60% crosslinking degree.
A drug release of 19.0 ± 0.8% was reached from PTXnano-GP-MS (40% crosslinked) after 21 days. A 7% burst 
release from PTXnano-GP-MS was seen during day 1 and PTX release was sustained during the entire drug release 
study. It has been reported that PTX nanocrystals exhibit a slower and more sustained release than Taxol® 46 and 
the incorporation of PTX nanocrystals into microspheres will further control the release rate of PTX.
PTX conc. in loading 
medium (mg/ml)
PTX load (µg) 
per mg MS
Incorporation efficiency 
(%)
PTX-ethanolic solution
1 1.1 ± 0.2 10.8 ± 2.1
2.5 1.4 ± 0.2 5.5 ± 0.7
5 3.4 ± 0.6 6.8 ± 1.2
PTX-nanosuspension
1 4.4 ± 0.7 43.6 ± 7.3
2.5 6.2 ± 0.5 24.7 ± 1.9
5 9.9 ± 0.8 19.7 ± 1.6
Table 3. Influence of PTX concentration (1, 2.5 and 5 mg/ml) and type of loading medium (ethanolic solution 
vs. nanosuspension) on PTX load and incorporation efficiency in GP-MS (n = 6). Microspheres with a 
crosslinking degree of 40% were used.
Crosslinking degree 
(%)
PTX load (µg) 
per mg MS
Incorporation efficiency 
(%)
7 4.2 ± 1.8 8.5 ± 3.6
25 4.0 ± 1.6 8.0 ± 3.1
40 3.4 ± 0.6 6.8 ± 1.2
60 2.5 ± 0.4 4.9 ± 0.8
70 1.8 ± 0.2 3.6 ± 0.5
Table 4. Influence of crosslinking degree on PTX load and incorporation efficiency in GP-MS (n = 6). 
Microspheres were loaded with a 5 mg/ml PTX-ethanolic solution.
Mass GP-
MS (mg)
Volume loading 
medium (ml)
PTX conc. in 
nanosuspension (mg/ml)
PTX load (µg) 
per mg MS
Incorporation 
efficiency (%)
100 2
1 12.3 ± 3.3 61.5 ± 16.7
2.5 18.9 ± 1.3 37.8 ± 2.6
5 28.7 ± 13.1 28.7 ± 13.1
50 2
1 16.6 ± 1.6 41.4 ± 4.1
2.5 30.5 ± 7.8 30.5 ± 7.8
5 39.2 ± 6.5 19.6 ± 3.3
200 3
1 10.7 ± 1.8 71.3 ± 12.1
2.5 16.5 ± 1.8 44.0 ± 4.8
5 27.6 ± 3.9 36.8 ± 5.3
Table 5. PTX load (µg) per mg GP-MS (n = 6) and incorporation efficiency in MS (n = 6). GP-MS mass, 
loading medium volume and PTX concentration in nanosuspension were varied during the incorporation 
procedure. Microspheres with a crosslinking degree of 40% were used.
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The absolute amount of PTX released from GP-MS was highest from microspheres loaded using the PTX 
nanosuspension (Fig. 2B) since more PTX could be incorporated into those microspheres. However, percentage 
drug release was higher for microspheres loaded with PTX ethanolic solution (Fig. 2A). This can partly be linked 
to PTX solubility in the release medium. Tween 80 was added to the release medium to increase PTX solubility, 
and literature reports solubility values of PTX in PBS with 0.1% Tween 80 in a 6 to 11 µg/ml range47,48. While the 
maximum PTX concentrations in release medium of PTXEtOH-GP-MS are within this range (8.4, 6.8 and 4.9 µg/ml 
for 7, 40 and 60% crosslinked microspheres, respectively), complete PTX release from PTXnano-GP-MS would 
largely exceed reported solubility values (78.4 µg PTX/ml in release medium). However, in vitro dissolution will 
be indicative for in vivo behaviour since sink condition will also not be reached in vivo because of the limited 
peritoneal fluid volume.
Influence of PTX-loaded GP-MS on ovarian cancer cell viability. Susceptibility of OC cells to 
PTX-GP-MS was determined based on ATP quantification by CellTiter Glo 2.0 Luminescent assay. In general, 
all PTX-GP-MS decreased viability of the cell lines in a time- and concentration-dependent manner, in order 
of sensitivity: SK-OV-3 Luc IP1 < SK-OV-3 < OVCAR-3. Since SK-OV-3 Luc IP1 cells are in vivo selected to 
mimic more aggressive disseminated cells34, higher IC50 values are expected. After 24 hours treatment, each cell 
type retained at least half of its viability. IC50 values after a treatment duration of 72 and 168 h were calculated 
to compare sensitivity of OC cells to the test formulations (Table 6). IC50 values of each test formulation were in 
the nanomolar range. Comparable IC50 values for OC cells exposed to PTX were found in literature although it 
should be noted that each value is influenced by the specific experimental conditions49–52. Antitumoral activity of 
PTX-GP-MS increased by prolonging exposure time since PTX is gradually released from the GP-MS. In compar-
ison, antitumoral activity of a PTX solution is faster, reflected in significantly lower IC50 values when compared to 
PTX-GP-MS in all cell lines after 72 h incubation. Over time, both PTX-GP-MS and PTX solution will eradicate 
OC cells with non-significant differences in IC50 values after 168 and 336 h incubation. Limited to no cell viability 
is observed after 336 h exposure to PTX treatment. Additionally, comparison of GP-MS with the same degree of 
crosslinking (40%) with a different type of loading medium showed that GP-MS loaded with a PTX nanosus-
pension displayed significantly lower IC50 values for the SK-OV-3 (Luc IP1) cell line. PTX nanosuspension is 
stabilized by Pluronic® F127 polymer. It is known that Pluronic block copolymers have cytotoxicity-promoting 
properties. They can sensitize tumor cells to cytostatic drugs and are able to inhibit multiple mechanisms of 
drug resistance in multi drug resistance (MDR) cancer. The chemosensitizing effect is most pronounced in 
Figure 2. Total cumulative PTX percentage (A) and PTX concentration (B) released as a function of time from 
GP-MS with different degrees of crosslinking (7, 40 and 60% for green, blue and red line, respectively) loaded 
with a 5 mg/ml PTX-ethanolic solution or from GP-MS with 40% crosslinking loaded with a 5 mg/ml PTX-
nanosuspension (grey line).
Cell line
7% crossl 
PTXEtOH-
GP-MS
25% crossl 
PTXEtOH-
GP-MS
40% crossl 
PTXEtOH-
GP-MS
60% crossl 
PTXEtOH-
GP-MS
40% crossl 
PTXnano-GP-
MS
PTX-
solution
IC50 values (nM) after 72 h treatment
SK-OV-3 28.1 ± 1.9 14.9 ± 2.2 18.3 ± 2.3 16.9 ± 1.8 8.6 ± 1.0 5.9 ± 0.9
OVCAR-3 8.2 ± 1.8 11.4 ± 2.2 12.1 ± 1.8 6.3 ± 1.8 9.5 ± 1.3 4.1 ± 1.8
SK-OV- 3 
Luc IP1 38.0 ± 2.3 27.1 ± 2.0 23.2 ± 2.0 16.6 ± 2.3 3.5 ± 2.4 7.1 ± 2.1
Cell line IC50 values (nM) after 168 h treatment
SK-OV-3 15.0 ± 2.7 7.9 ± 1.8 22.9 ± 2.2 7.2 ± 1.9 4.9 ± 1.8 7.5 ± 1.9
OVCAR-3 4.7 ± 1.7 6.3 ± 1.7 9.5 ± 1.8 4.5 ± 1.7 7.1 ± 1.7 4.1 ± 1.7
SK-OV-3 
Luc IP1 11.2 ± 6.0 37.2 ± 2.3 16.1 ± 2.0 30.3 ± 2.3 10.3 ± 1.5 25.9 ± 1.9
Table 6. IC50 values of PTX after SK-OV-3 (Luc IP1) and OVCAR-3 cells were treated during 72 and 168 h with 
PTX-GP-MS and PTX-solution. Mean IC50 and SD of triplicates are shown.
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MDR cancer cell lines, but it is also observed in regular cancer cells including SK-OV-3 cells13,53,54. This was not 
observed for OVCAR-3 cells since their susceptibility to PTX is higher and IC50 values were similar for all PTX 
treatments.
Efficacy of PTX-microspheres in a microscopic peritoneal carcinomatosis xenograft 
model. Survival curves of control and PTX-treated animals are displayed in Fig. 3. Subsequent survival com-
parison using the log-rank test for trend showed a significant inferior survival of control animals (0.9% saline and 
blank GP-MS-treated mice, p < 0.05) compared to animals who received a treatment with a PTX formulation. 
Median survival time is displayed in Table 7.
A median survival of 33 and 36 days was observed after IP administration of 0.9% saline and blank GP-MS, 
respectively. There was no significant difference in survival outcome between both control groups. IP administra-
tion of a PTX treatment after IP xenograft inoculation significantly increased survival of the animals. However, 
there were no significant differences in survival outcome observed between the different treatment groups. A 
median survival of 68 days was seen after IP treatment with PTXEtOH-GP-MS dosed at 7.5 mg PTX/kg with ILS 
of 35 days compared to untreated animals. At the final day of the study, 40.0% of the PTXEtOH-GP-MS-treated 
animals remained alive. Following IP administration of PTXnano-GP-MS, dosed at 7.5 and 35 mg PTX/kg, 63.6% 
of the PTXnano-GP-MS-treated mice of both dosage groups were still alive upon completion of the survival study. 
The median survival time was not reached for PTXnano-GP-MS. An ILS of at least 57 days compared to untreated 
animals was noticed. It should be remarked that the events of death happened at earlier time points for the 
high-dosed PTXnano-GP-MS group (day 24, 26 and 33 post-treatment), whereas in the low-dosed group, deaths 
occurred at day 47, 62 and 69 post-treatment. It is possible that the deaths in the high-dosed PTXnano-GP-MS 
were treatment-related, while they were related to progression of the disease in the low-dosed group. In contrast 
to the pronounced survival prolongation due to the slow release of PTX from PTX-GP-MS and thus the longer 
residence time of PTX in the abdominal cavity, an ILS of 12.5 days and %ILS of 37.9% was achieved after bolus 
injection of nab-PTX (35 mg PTX/kg). 41.7% of the nab-PTX treated animals remained alive until completion 
of the study.
PCI scores of the control and drug-treated mice are plotted in Fig. 4A. Comparison of the PCI scores of 
the different treatment groups demonstrated that there were no significant differences between the two control 
groups or between the PTX-treatment groups. Significant differences in PCI score were observed when compar-
ing PCI scores of mice treated with 0.9% saline versus mice treated with PTXEtOH-GP-MS (p = 0.0035); versus 
PTXnano-GP-MS (p < 0.0001, both dose groups) and versus nab-PTX (p = 0.0205). Also, significant differences in 
PCI score were seen when comparing blank GP-MS and PTXnano-GP-MS dosed at 7.5 mg PTX/kg (p = 0.0001) 
and dosed at 35 mg PTX/kg (p < 0.0001). When comparing PCI scores of blank GP-MS-treated mice to the scores 
of mice treated with PTXEtOH-GP-MS or nab-PTX, no significant differences could be observed.
High PCI scores of 34.4 ± 2.2 and 30.2 ± 5.4 were assigned to the 0.9% saline and blank GP-MS treated ani-
mals, respectively. Numerous small tumor nodules were found in the abdominal cavity at the visceral peritoneum 
Figure 3. Kaplan-Meier survival curve of mice treated with control (0.9% saline, blank GP-MS) or PTX-
formulation (PTXEtOH-GP-MS (D = 7.5 mg PTX/kg), PTXnano-GP-MS (D = 7.5 or 35 mg PTX/kg) or 
nanoparticular albumin-bound PTX, nab-PTX (D = 35 mg/kg)). Mice treated with a PTX-formulation lived 
significantly longer than mice treated with a control in a microscopic peritoneal disease xenograft model.
Treatment
Dose PTX 
(mg/kg) MST (d) ILS (d) %ILS
0.9% saline 0 33 NA NA
blank GP-MS 0 36 NA NA
PTXEtOH GP-MS 7.5 68 35 106.1
PTXnano GP-MS 7.5 90 57 172.7
PTXnano GP-MS 35 90 57 172.7
nab-PTX 35 45.5 12.5 37.9
Table 7. Median survival time (MST) of mice after IP administration of different treatments in a microscopic 
peritoneal carcinomatosis xenograft model and observed increase in life span (ILS) compared to control 
animals receiving an IP injection of 0.9% saline. NA = non-applicable; nab-PTX = nanoparticular albumin-
bound paclitaxel.
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and mesentery, and tumor infiltration into liver, spleen, stomach and diaphragm was also observed (Fig. 5-1 and 
5-2). Omental metastases were found in 90.9% and 80.0% of the mice in the 0.9% saline and blank GP-MS group, 
respectively.
Whereas all control mice developed peritoneal carcinomatosis (PC) in a similar manner, cancer did not pro-
gress in the same way in the PTX-treated mice. Treatment with PTXEtOH-GP-MS was successful to eradicate 
microscopic disease and to prevent tumor progression in 4 of the 10 animals (Fig. 5-3A). However, despite a 
lack of PC, tumor growth was seen in 3 of the 4 animals at the site of injection. During removal of the injection 
needle from the peritoneal space, a remainder of the SK-OV-3 Luc IP1 cell suspension was possibly released in 
the subperitoneal space between the skin and abdominal muscle layer. Because of the potency of the cell line 
after in vivo selection this could result in a local tumor node despite a low number of cells inoculated34. Five of 
the PTXEtOH-GP-MS-treated animals developed PC (Fig. 5-3B). Three animals died from disease progression 
post-treatment day 32, 34 and 49, similar to the survival of control animals. The treatment had no effect on 
microscopic peritoneal disease. Two animals died at day 62 and 74 post-treatment. In these animals, sustained 
PTX release from PTXEtOH-GP-MS prolonged survival, but it was insufficient to prevent recurrence of peritoneal 
disease. In one animal, a large tumor developed dorsally while the typical pattern of numerous small peritoneal 
nodules was not observed.
Seven of the PTXnano-GP-MS-treated animals, dosed at 7.5 mg PTX/kg, did not develop PC and no other local 
tumors were detected (Fig. 5-4B). Sustained release of PTX from GP-MS loaded with a PTX nanosuspension was 
effective to eliminate microscopic disease and could prevent recurrence of peritoneal disease during the period 
of the survival study. While one animal grew a local tumor subperitoneally following a spill of tumor cells during 
withdrawal of the needle after IP injection for tumor inoculation, it did not develop peritoneal carcinomatosis. 
Three of the eleven animals died because of large dorsal tumor nodules, as illustrated in Fig. 5-4A. The typical 
IP dissemination pattern of peritoneal disease was not observed in those animals, but the large dorsal tumor 
mass was correlated with cachexia with a weight loss of 7, 15 and 17%. The other animals of this treatment 
group gained weight. PTXnano-GP-MS treated animals, dosed at 35 mg PTX/kg, displayed no PC upon autopsy, 
including the four animals who died before completion of the study. Only 1 animal developed a local tumor node 
subperitoneally.
The nab-PTX-treated mice could be divided into responders and non-responders. The mice either developed 
peritoneal carcinomatosis with a high PCI score at the time of autopsy (58.3% of the animals, Fig. 5,6A) or a single 
injection of a high dose of the immediate release nab-PTX formulation was efficient for the prophylaxis of PC 
recurrence (41.7% of the animals, Fig. 5,6B).
When comparing the weight change of the mice (Fig. 4B), no significant differences could be observed 
between the groups. No unambiguously conclusions can be derived from weight change over time since an 
increase in weight is not always related to an efficacious treatment. While extreme weight loss is evidently related 
Figure 4. Antitumor efficacy of control groups (0.9% saline (n = 11) and blank GP-MS (n = 11)) and treatment 
groups (PTXEtOH-GP-MS (D = 7.5 mg PTX/kg, n = 10), PTXnano-GP-MS (D = 7.5 or 35 mg PTX/kg, n = 11/
group) and nanoparticular albumin-bound PTX, nab-PTX (D = 35 mg PTX/kg, n = 12)) in microscopic 
peritoneal disease xenografts, based on (A) peritoneal carcinomatosis index (PCI), (B) percentage weight 
change and (C) ascites score. Bars indicate median and interquartile range.
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to disease progression, ascites - which increases the body weight - is associated with peritoneal metastases and a 
poor prognosis55.
Ascites scores of each mouse per group are plotted in Fig. 4C. Ascites was present in 90.9% and 70.0% of the 
mice who received an IP injection of 0.9% saline or blank GP-MS, respectively. Treatment with PTXnano-GP-MS, 
at both dosages, significantly decreased incidence of ascites compared with animals treated with 0.9% saline 
(p = 0.0016) and blank GP-MS (p = 0.0082). None of the PTXnano-GP-MS treated mice had ascites present at the 
time of death or at the end of the study. No significant differences in ascites score were observed when control 
groups were compared with PTXEtOH-GP-MS or nab-PTX treated animals. Ascitic fluid was observed in 50.0 and 
54.5% of PTXEtOH-GP-MS and nab-PTX treated mice, respectively. Additionally, the incidence of ascites was sig-
nificantly lower for animals treated with PTXnano-GP-MS compared with animals treated with PTXEtOH-GP-MS 
(p = 0.0190) or nab-PTX (p = 0.0143).
BLI images of representative mice are displayed in Fig. 6. A longitudinal follow-up of tumor burden and effect 
of the applied therapies on microscopic PC was possible during the survival study. BLI signals of the individual 
mice of each group during the survival study are displayed in Suppl. Fig. 1.
An increase of BLI signal over time was seen in all control animals, related to the progression of peritoneal 
carcinomatosis. Maximal total flux of 1.9 × 109 and 1.85 × 109 p/s was measured in animals treated with 0.9% 
saline and blank GP-MS, respectively. Follow-up of the BLI signals of drug-treated animals allowed to individ-
ually monitor the efficacy of the administered treatment. An effective response of PTX treatment over time was 
seen when BLI signal remained low (baseline signal, total flux of 104–105 p/s) and constant during the entire 
study due to eradication of initial microscopic peritoneal disease. When the BLI signal increased, the treatment 
failed to (further) prevent relapse of peritoneal disease. As seen in the PTXEtOH-GP-MS and nab-PTX groups, 
when the proton flux started to increase, the animal started to develop PC with maximal total flux of 3.42 × 109 
and 7.44 × 108 p/s, respectively. Similarly, the increase of total flux in some animals of the PTXnano-GP-MS group, 
indicated the presence of a tumor with a maximal measured total flux of 3.52 × 109 p/s. Combination of the BLI 
images and semi-quantitative proton flux data allowed for a careful monitoring of disease progression and eval-
uation of the extent of disease. Data of the total flux alone do not provide information about the localization of 
the tumor(s). When analyzing BLI images, it is clear that the animals in the PTXEtOH-GP-MS-group where proton 
flux increased, had a widespread distribution of tumor cells in the abdominal cavity, while animals with increas-
ing BLI signal in the PTXnano-GP-MS group, dosed at 7.5 mg/kg, showed a localized tumor growth. Additionally, 
shifts of BLI signal can be used as an indication of the optimal time point to re-administer the therapy.
Histopathology and toxicity. Histopathological analysis of the major abdominal organs and peritoneal 
tissue was performed to evaluate the extent of peritoneal disease and possible local toxicity of the different treat-
ments. Microphotographs of H&E-stained tissues of the mice of different treatment groups are displayed in Fig. 7.
Numerous tumor nodules consisting of actively dividing cells were clearly visible in the mesentery of the jeju-
num in control mice. It is known that malignant cells quickly and efficiently invade the mesentery because of its 
Figure 5. Macroscopic images of intraperitoneal dissemination. Control animals (0.9% saline (1) and blank 
GP-MS (2) display peritoneal carcinomatosis. PTXEtOH-GP-MS treated animals (3) either developed peritoneal 
carcinomatosis (3A) or remained disease-free (3B). PTXnano GP-MS treated animals either developed in a few 
cases a local tumor node (4A, arrow) or remained disease free (4B, 5). Animals treated with nanoparticular 
albumin-bound PTX, nab-PTX, either developed peritoneal carcinomatosis (6A) or not (6B).
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unique microvasculature56. Morphology of the jejunum of control mice was normal with no signs of inflamma-
tion or tumor cells in the mucosa, indicating that the tumor cells only invaded visceral peritoneal tissue. Liver tis-
sue of control mice not only showed tumor cells at the capsule of the liver, but tumor cells had also infiltrated the 
liver parenchyma (Fig. 8-1C). The gall bladder of control animals was also metastasized with tumor cells as illus-
trated in the photomicrograph of a liver of a mouse treated with 0.9% saline in Fig. 7. When peritoneal disease 
had extended into the liver, several liver disorders were seen as displayed in Fig. 8. Necrotic hepatic disease was 
observed (1A-D). This phenomenon is typically seen in rapidly growing hepatic metastasis, causing hypoxia and 
subsequently necrosis. Rupture of tumor blood vessels in necrotic areas may result in massive hemorrhage and 
peliosis hepatis57 (Fig. 8-1D). Parietal peritoneum of control mice showed active inflammation of mesothelium 
with the presence of tumor cells of ovarian origin as confirmed by a positive PAX-8 staining (Suppl. Fig. 2). In 
most cases, peritonitis and tumor development remained localized at the mesothelium, but in a few cases exten-
sion of the inflammation into muscle tissue of the abdominal wall was observed (blank GP-MS). Large tumor 
nodules were present in the adipose tissue of the omentum and splenoportal fat of control mice. They are known 
preferential sites for tumor cell attachment because of their vascularization and the presence of immune aggre-
gates, ‘milky spots’56. Tumor tissue of control mice was vascularized and consisted of actively dividing tumor cells, 
but also regions of necrosis were observed, typically seen in locally advanced solid tumors. Prolonged hypoxia, 
imbalance between oxygen consumption and supply, can cause necrosis. Reasons for hypoxia in tumors include 
Figure 6. Representative in vivo bioluminescence images of IP tumor burden in different control (IP injection 
of 0,9% saline or blank GP-MS) and treatment groups (IP injection of PTXEtOH-GP-MS (D = 7.5 mg PTX/kg), 
PTXnano-GP-MS (D = 7.5 mg PTX/kg or D = 35 mg PTX/kg), nanoparticular albumin-bound PTX, nab-PTX 
(D = 35 mg PTX/kg)).
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an abnormal structure and function of microvessels supplying the tumor, a longer diffusion distance between 
blood vessels and tumor cells and a lower oxygen transport capacity of blood58,59.
Positive PAX-8 staining of the tissues of control mice confirmed that tumor cells were of ovarian origin (Suppl. 
Fig. 2).
H&E staining (Fig. 7) of jejunum tissue of mice treated with PTXEtOH-GP-MS showed either the presence of 
metastases of ovarian origin (positive PAX-8 staining, Suppl. Fig. 2) in the mesentery or no metastases in case 
of response to the treatment. In both cases, the architecture of the small intestines showed no irregularities or 
abnormalities. When the treatment was ineffective, liver metastases were found at the surface of the liver in com-
bination with infiltration of tumor cells into liver parenchyma with hepatic necrotic disease. Liver tissue of mice 
Figure 7. Optical micrographs of H&E-stained sections of jejunum, liver, peritoneum, spleen, pancreas 
and tumor of untreated (0.9% saline, blank GP-MS) or PTX-treated (PTXEtOH- or PTXnano-GP-MS and 
nanoparticular albumin-bound PTX, nab-PTX) mice in a microscopic peritoneal carcinomatosis xenograft 
model of ovarian origin.
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who responded to the PTXEtOH-GP-MS-treatment displayed a normal morphology. In the mesothelial lining of 
the peritoneum covering the abdominal wall, more inflammatory and tumor cells of ovarian origin were detected, 
as confirmed by a positive PAX-8 staining. However, when the release of PTX from PTXEtOH-GP-MS was effective 
to treat microscopic peritoneal disease, the peritoneum and skeletal muscle of the abdominal wall displayed a 
normal morphology. Similar to the control mice, omental metastases were found in mice who did not respond 
to PTXEtOH-GP-MS treatment. A dense, solid tumor was observed and tumor cells were attached to the richly 
vascularized adipose tissue of omental tissue associated to spleen and pancreas, without affecting the architecture 
of the organs itself.
The high response rate to the PTXnano-GP-MS treatment, dosed at 7.5 mg/kg PTX, was reflected upon histo-
logical examination of abdominal organ tissues. No tumor cells or abnormalities were seen in tissues of jejunum, 
liver, spleen and pancreas. As observed via BLI imaging and during autopsy, some mice developed a local tumor 
nodule at the site of injection, which was confirmed upon histopathological examination. A large dense tumor 
node invaded the mesothelial lining of the peritoneum into the skeletal muscle of the abdominal wall. Blood 
vessels were present in the tumor nodule. PAX-8 expression confirmed that the tumor cells were of ovarian ori-
gin. Additionally, evaluation of tumor tissue of the 3 mice who developed a large dorsal tumor showed extended 
regions of tumor necrosis. This can be either attributed to the typical observations of large localized tumor nod-
ules where the imbalance between oxygen supply and use results in necrosis.
Histopathological observation of H&E stained tissues of mice who received PTXnano-GP-MS treatment, dosed 
at 35 mg PTX/kg, confirmed that there was no peritoneal carcinomatosis present. Tissues of small intestines, 
peritoneum, pancreas and spleen had a normal appearance. However, while most of the liver tissue showed no 
abnormalities, liver tissues of 3 animals clearly confirmed sinusoidal dilatation with congestive central veins (i.e. 
sinusoidal obstruction syndrome) and the presence of peliosis hepatis. The syndrome was especially pronounced 
in one animal (Fig. 8-2). Little is known about the effects on the liver of a prolonged IP PTX release. Sinusoidal 
congestion was observed in liver tissue of high dose PTXnano-GP-MS treated mice who died prior to the end of the 
study, whereas liver tissue of mice who remained alive until the end of the study did not show abnormalities. It is 
possible that the mice died of treatment-related toxicity because of the prolonged exposure to a higher concentra-
tion of PTX, resulting in a high portal vein PTX concentration and higher hepatoxicity, since no hepatoxicity was 
noticed when mice were treated with PTXnano-GP-MS dosed at 7.5 mg PTX/kg.
IP treatment with a bolus injection of 35 mg/kg nab-PTX resulted in either an effective treatment of micro-
scopic peritoneal disease, which was reflected by a normal histological appearance of jejunum, liver, peritoneum 
and spleen, or the immediate release of nab-PTX appeared to be ineffective. This latter was reflected by tumor 
nodules in the mesentery of jejunum and ileum, infiltration of liver parenchyma and capsule with tumor cells 
(as confirmed by positive PAX-8 staining), omental metastases with tumor cells - in the connective and adipose 
tissue associated to the spleen and tumor cells in the mesothelium of the parietal peritoneum. The tumor tissue 
consisted of a dense population of tumor cells, with blood vessels present and also regions of tumor necrosis. Two 
cases showed a congestive liver with sinusoidal obstruction, which could be either attributed to tumor infiltration 
into the liver or to the high chemotherapy dose.
Pharmacokinetics of PTX-treatments. Average systemic and average predicted local peritoneal PTX 
concentrations after IP administration of the different PTX treatments (PTX-GP-MS and nab-PTX) as a function 
of time are displayed in Fig. 9. A burst release was observed during the first day after IP injection of PTX-GP-MS 
followed by a sustained release of PTX from PTX-GP-MS over the period of the in vivo drug release study, result-
ing in a prolonged systemic exposure to PTX but at a low concentration level. Higher local PTX concentrations 
Figure 8. Optical micrographs of liver irregularities of H&E-stained slices of livers of control, PTXnano-GP-MS 
or nab-PTX-treated mice (D = 35 mg PTX/kg). Liver tissue of control mice (1A–D) displayed areas of necrosis, 
indicated by an arrow. Tumor cells infiltrated liver parenchyma (1C). Massive infiltration of SK-OV-3 Luc IP1 
cells eventually leads to hemorrhage and peliosis hepatis (1D). A case of sinusoidal obstruction syndrome was 
observed in a PTXnano-GP-MS treated mice (2) and sinusoidal congestion was also noticed in nab-PTX-treated 
mice.
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were obtained compared to systemic PTX concentrations because of the prolonged peritoneal PTX release from 
the GP-MS and a slow systemic absorption.
Pharmacokinetic parameters of average systemic and peritoneal PTX concentrations are displayed in Table 8. 
Burst release was higher after IP administration of PTXEtOH-GP-MS compared to PTXnano-GP-MS: Cmax in blood 
and peritoneal fluid were respectively 5.9 and 7.1-fold higher for PTXEtOH-GP-MS compared to PTXnano-GP-MS 
at a dose of 7.5 mg PTX/kg. Remarkably, peak peritoneal and blood concentration of PTX released from 
PTXEtOH-GP-MS (D = 7.5 mg PTX/kg) were also higher when compared to PTXnano-GP-MS, at a dose of 35 mg 
PTX/kg. A dose-proportional increase of AUC0-∞ and Cmax was seen when the dose was escalated to 35 mg PTX/kg, 
indicating linear pharmacokinetics.
Nab-PTX, the nanoparticulate formulation of PTX, was unable to sustain the PTX release over a prolonged 
period of time which is reflected in its different PK profile. PTX was rapidly absorbed from the peritoneal cavity 
into the systemic circulation, while GP-MS released PTX more gradually. 24 hours after IP injection of nab-PTX, 
54% of the PTX-dose was systemically absorbed. In contrast, only 7 and 4% PTX was systemically absorbed 
24 hours after IP administration of PTXEtOH-GP-MS and PTXnano-GP-MS, respectively. After 14 days, approx-
imately 10–15% of the PTX amount released from GP-MS was systemically absorbed. Additionally, since the 
PTX dose is rapidly released after IP administration of nab-PTX, significantly higher peak concentrations were 
observed compared to the slow PTX release from PTXnano-GP-MS at the same dose, both systemically and locally. 
Figure 9. Average predicted PTX concentration (ng/ml) as a function of time after IP administration of 
different types of PTX-GP-MS (PTXEtOH-GP-MS at a dose of 7.5 mg PTX/kg and PTXnano-GP-MS at doses of 
7.5 and 35 mg PTX/kg) in blood (A) and peritoneal fluid (C) of mice. PTX concentrations were detectable up 
to 14 days. In contrast, (B,D) represent the predicted average PTX concentration after a single IP injection of 
nanoparticular albumin-bound PTX, nab-PTX (D = 35 mg PTX/kg) in blood and peritoneal fluid, respectively.
Treatment
PTX dose 
(mg/kg)
AUC0–14d 
(µg.h/ml)
AUC0-∞ 
(µg.h/ml) Cmax (µg/ml) tmax (h)
Average systemic PTX concentrations
PTXEtOH-GP-MS 7.5 0.6 0.7 0.06 2.5
PTXnano-GP-MS 7.5 0.4 0.7 0.01 4.9
PTXnano-GP-MS 35 1.6 3.1 0.04 5.0
Nab-PTX 35 9.1 10.7 1.6 2.5
Average peritoneal PTX concentrations
PTXEtOH-GP-MS 7.5 46.8 49.8 5.6 1.5
PTXnano-GP-MS 7.5 31.7 52.9 0.8 3.05
PTXnano-GP-MS 35 119.5 203.1 3.0 3.05
Nab-PTX 35 676.9 677.1 153.6 1.5
Table 8. Pharmacokinetic parameters of average systemic and peritoneal PTX concentration-time profiles: 
area under the curve (AUC), peak concentration (Cmax) and time to peak concentration (tmax) of the different IP 
treatment groups Nab-PTX = nanoparticular albumin-bound PTX.
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The higher percentage absorption and high systemic PTX peak concentration may result in systemic side effects 
such as neutropenia.
Individual peritoneal PTX profiles are displayed in Suppl. Fig. 3. Despite between-animal variability in peak 
PTX concentration, a higher burst release was not the predictive factor for differences in treatment response. 
In the PTXEtOH-GP-MS and nab-PTX-treated mice, there were either ‘treatment-responders’ when micro-
scopic peritoneal disease was successfully eradicated, and PC did not recur, or ‘treatment-non-responders’ 
when PC did develop. However, no significant differences were found in peak peritoneal PTX concentrations of 
‘treatment-responders’ and ‘treatment-non-responders’ within the PTXEtOH-GP-MS and nab-PTX-groups.
Evaluation of ccCK18 as a biomarker in ovarian cancer. Average concentrations of caspase-cleaved 
cytokeratin 18 (ccCK18) over time measured in plasma of mice treated with the different therapies (control, 
PTX-GP-MS and nab-PTX) are shown in Fig. 10.
An increase of ccCK18 concentration was observed for the control animals related to disease progression. 
Thus, the development of peritoneal carcinomatosis could be monitored via the evolution of ccCK18 in time.
Monitoring of ccCK18 levels of the PTX treatment groups showed elevated ccCK18 levels during the first 30 
days. In case of the PTXEtOH-GP-MS and nab-PTX treated mice, this can be explained in two ways. Treatment 
non-responders developed peritoneal carcinomatosis and elevated ccCK18 levels were seen because of spon-
taneous apoptosis of tumor cells. On the other hand, elevated ccCK18 concentrations were also observed in 
treatment-responders because of PTX-induced apoptosis of SK-OV-3 IP1 Luc cells. After absorption of PTX 
from the abdominal cavity, ccCK18 returns to a baseline level. Individual ccCK18 profiles of representative mice 
treated with PTXEtOH-GP-MS are displayed in Suppl. Fig. 4 where it is clearly seen that animals 7 and 11 were 
non-responders, and animals 1, 4 and 8 treatment-responders. Animal 5 showed an increase of ccCK18 after 58 
days, which can be linked to a relapse of peritoneal disease after initial treatment response.
All PTXnano-GP-MS-treated animals had elevated ccCK18 levels during the first month due to drug-induced 
apoptosis of SK-OV-3 IP1 Luc cells caused by the local prolonged PTX release from the PTXnano-GP-MS. PTX 
was measurable up to 14 days in blood, but in vitro studies demonstrated that PTX-microspheres were able to 
sustain PTX concentrations up to 21 days. After 1 month, PTX will be completely absorbed from the peritoneal 
cavity and ccCK18 levels return to a baseline level until completion of the survival study.
Previous studies have shown that there is a significant correlation between ccCK18 and drug-induced toxicity, 
e.g. damage to normal tissue. However, because the M30 Apoptosense® assay is human specific and should only 
detect ccCK18 released by human xenograft tumor cells, interference due to cell death of normal epithelial tissues 
of mice should be limited60.
Discussion
Randomized controlled clinical trials have shown that the addition of IP chemotherapy to the first-line treatment 
cytoreductive surgery and platinum-taxane based IV chemotherapy increased overall survival and disease-free 
progression of patients with advanced ovarian cancer1,2,17. Nevertheless, prognosis of the disease remains poor 
due to a high percentage of recurrence. Approximately 80% of advanced OC patients will relapse within 5 years. It 
is assumed that the high rate of recurrence can be attributed to the short residence time of chemotherapeutics in 
the abdominal cavity1,3,8,18,20. Therefore, a post-surgical adjuvant IP treatment able to sustain an anticancer agent 
in the abdomen for weeks or even months is of high clinical interest. Therefore, we evaluated PTX-GP-MS as a 
novel IP drug delivery system.
Our in vitro data suggest that PTXnano-GP-MS are most promising for IP drug delivery. The highest amount 
of PTX could be incorporated into GP-MS when GP-MS were immersed in a PTX-nanosuspension. Also, PTX 
loading could be most easily varied, offering a flexible therapeutic strategy. Subsequently, released PTX con-
centrations were highest both during in vitro and in vivo release. Additionally, the sustained release profile of 
PTXnano-GP-MS was more favorable compared to PTXEtOH-GP-MS.
In vivo results showed that PTX-treatment significantly improved survival of mice in a microscopic perito-
neal carcinomatosis mouse model. No significant differences in survival outcome were observed between the 
different PTX-treatment groups. The survival study was ended 90 days post-treatment, an increase of the study 
period could be required to obtain more conclusive results. However, mice treated with IP PTXnano-GP-MS, 
at both dose levels, increased the life span with at least 57 days compared to an increase of 35 and 12.5 days 
Figure 10. Average concentration of ccCK18 (U/L) as a function of time measured in plasma samples of 
different control (IP injection of 0,9% saline or blank GP-MS) and treatment groups (IP injection of PTXEtOH-
GP-MS (D = 7.5 mg PTX/kg), PTXnano-GP-MS (D = 7.5 mg PTX/kg or D = 35 mg PTX/kg), nanoparticular 
albumin-bound PTX, nab-PTX (D = 35 mg PTX/kg)) in a human xenograft microscopic peritoneal 
carcinomatosis mouse model.
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following IP treatment with PTXEtOH-GP-MS (D = 7.5 mg PTX/kg) and nab-PTX (D = 35 mg PTX/kg), respec-
tively. Additionally, IP treatment with PTXnano-GP-MS significantly decreased PCI score compared to both 
control groups, whilst no differences of PCI score could be observed when comparing PTXEtOH-GP-MS and 
nab-PTX-treated animals to animals treated with blank GP-MS. Furthermore, treatment with PTXnano-GP-MS 
significantly decreased the presence of ascites compared to mice treated with blank GP-MS and 0.9% saline. In 
contrast, the presence of ascites did not differ after an IP treatment with PTXEtOH-GP-MS or nab-PTX compared 
to the controls. These results support that PTXnano-GP-MS seem to present a promising and effective post-surgical 
adjuvant IP treatment strategy.
A prolonged residence of PTX in the abdominal cavity clearly improved treatment outcome and progression 
free survival of mice compared to a single IP injection with nab-PTX. Despite a high Cmax of 154 µg/ml in peri-
toneal fluid following IP administration of nab-PTX, the formulation is quickly absorbed from the peritoneal 
cavity with a high systemic peak concentration. After one day, PTX was not detectable anymore in blood or 
peritoneal fluid. In contrast, PTX remained detectable both in blood and peritoneal fluid up to 14 days following 
IP treatment with PTX-GP-MS. Although both PTXEtOH- and PTXnano-GP-MS were able to prolong the residence 
time of PTX in the abdominal cavity, PTXnano-GP-MS were more efficacious in eradicating minimal peritoneal 
disease and preventing recurrent peritoneal carcinomatosis. It has already been reported that PTX nanocrystals 
demonstrate a high cellular uptake due to their size and accumulate in tumor tissue, increasing the efficacy of 
PTX therapy13,61,62.
As systemic absorption of a chemotherapeutic agent from a local drug depot system is limited, systemic toxic-
ity will be largely avoided. But little is known about the influence of a prolonged residence time of a chemothera-
peutic agent on normal tissues and organs of the abdominal cavity. Three mice (27%) receiving PTXnano-GP-MS 
at a 35 mg PTX/kg dose showed liver toxicity (sinusoidal dilation and congestive veins in liver parenchyma), while 
no abnormalities were seen in other abdominal organs and peritoneal tissue. Additionally, hematological analysis 
showed no deviations of white blood cell count, absolute neutrophil count, platelets and other parameters. This 
hepatoxicity can be a complication of chemotherapy as it is known that several chemotherapeutic agents have 
a toxic effect on the liver, inducing injuries on hepatic venous endothelium and consequently the sinusoidal 
obstruction syndrome. This phenomenon is most frequently described following administration of 5-fluorouracil, 
cyclophosphamide and oxaliplatin and is rarely seen in paclitaxel therapy63–66. However, elevated liver function 
values (bilirubin, alkaline phosphatase (ALP), aspartate and alanine aminotransferase (AST and ALT, respec-
tively)) were reported in patients receiving IV PTX therapy, although the liver values rarely largely exceeded the 
upper limits of normal ALP, AST or ALT values and are dose dependent67–73. Liver injury is a direct effect of PTX 
since the molecule is predominantly metabolized by the liver74. Morbidity and adverse effects reported during 
IP treatment with PTX are mostly abdominal pain and hematological and neurologic toxicity1,17,75. Although an 
increase in hepatic injury was reported by Armstrong et al., the peritoneal clearance of paclitaxel might have been 
altered because the drug was given after IP cisplatin2. The prolonged peritoneal exposure to a higher PTX concen-
tration might have resulted in a high portal vein PTX concentration, and higher hepatotoxicity since no hepato-
toxicity was observed when mice were treated with PTXnano-GP-MS dosed at 7.5 mg PTX/kg. Monitoring of liver 
values and portal vein concentrations will be recommended and prophylactic administration of anti-oxidants or 
glutathione could overcome the toxicity syndrome76.
A pharmacokinetic-pharmacodynamic (PKPD) model accounting for the positive drug treatment effect and 
unwanted toxicity of PTX-treatment on survival of mice in a microscopic peritoneal carcinomatosis model was 
developed (unpublished model based analysis). Dose simulations of PTXnano-GP-MS from the developed PKPD 
model demonstrated that the optimal dose of PTXnano-GP-MS to achieve a good survival outcome with minimal 
drug-related toxicity ranged from 7.5 to 15 mg PTX/kg. Sustained PTX release in a low dose is thus effective to 
prevent recurrence of peritoneal disease, thereby avoiding local toxic side-effects because of the prolonged pres-
ence of PTX in the abdominal cavity.
Finally, this work evaluated ccCK18 as a biomarker to monitor drug-response and efficacy. Cytokeratin-18, 
a protein present in epithelial cells, is cleaved by caspases during apoptosis. The resulting fragments, 
caspase-cleaved cytokeratin-18, are release into the blood77–79. Longitudinal follow-up of ccCK18 concentration 
in serum or plasma could be interesting to monitor treatment response since the anticancer activity of PTX 
can be directly related to the induction of apoptosis of tumor cells77,79. Furthermore, the correlation between 
drug-induced tumor cell apoptosis and an increase in ccCK18 has already been proven80–82.
Elevated ccCK18 levels were observed during the first month of the survival study, indicating drug-induced 
apoptosis of tumor cells. An increase of ccCK18 is expected when PTX induces mitotic arrest and apoptosis of 
SK-OV-3 IP1 Luc cells, thereby demonstrating the potential of ccCK18 as a predictive biomarker for treatment effi-
cacy. However, interpretation of ccCK18 is complex because release of ccCK18 can be a response to various stimuli 
including treatment response, drug-induced toxicity and increase of tumor burden. A correlation was observed 
between elevated levels of ccCK18 and tumor burden. It has already been shown that patients with epithelial car-
cinomas have elevated levels of (cc)CK18 related to the spontaneous apoptosis of tumor cells. Higher levels of 
ccCK18 have been associated to the number of involved organs, performance status and shorter median survival60. 
Nevertheless, a positive correlation between increased ccCK18 levels and treatment response was observed in this 
study and in several other (pre)clinical trials60,77,78,81. Therefore, the inclusion of ccCK18 in a biomarker panel (cancer 
antigen 125, human epididymis protein 4, e-cadherin,…)83–85 in ovarian cancer therapy should not be neglected.
Our preclinical results in mice are promising for further investigation of the effectiveness of PTX-GP-MS in the 
treatment of peritoneal carcinomatosis of ovarian origin. Low-dosed PTXnano-GP-MS seem to be most promising 
postsurgical IP adjuvant formulation with a significant improvement of survival, little systemic absorption and no 
toxicity is observed while maintaining a sustained release of PTX over 14 days. Prior to a first-in-human phase I 
trial, pharmacology and toxicology studies should be performed in a rodent and non-rodent species and the most 
sensitive species will be chosen for safe starting dose determination taking into account a conversion factor86.
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conclusion
This study in a human xenograft microscopic peritoneal carcinomatosis mouse model showed that prolonging 
the residence time of PTX in the abdominal cavity is an effective way to improve treatment outcome of advanced 
ovarian cancer. PTXnano-GP-MS was the most effective formulation to eradicate microscopic peritoneal carcino-
matosis and to prevent recurrent peritoneal disease. Life span of mice improved with a significant reduction of 
tumor burden based on PCI score, BLI imaging and ascites incidence compared to control animals. In contrast, 
no significant differences in PCI score and presence of ascites were observed when comparing PTXEtOH-GP-MS 
and nab-PTX treated animals to control animals. PTXnano-GP-MS seem to be a promising postsurgical adjuvant 
IP depot system. Previous work already demonstrated the effectiveness of GP-MS to prevent peritoneal adhesions 
in a mouse model, a common complication after CRS. The promising preclinical results and the potential dual 
application of the concept in the treatment modality of advanced ovarian cancer mark their clinical relevance and 
encourage further (pre)clinical evaluation of the formulation.
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